SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SARS and Avian Flu
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Elroy Jetson who wrote (2745)10/16/2005 11:56:51 PM
From: Amy J  Read Replies (1) of 4232
 
RE: "The underlying problem is there is very marginal private demand for flu vaccines"

No, the problem is the flu companies don't directly sell to consumers, but instead you've got HMOs that decide on quantity.

If the flu vaccine companies enabled direct sales to the consumers, where consumers could pay $20 in advance to guarantee their vaccine, the flu companies probably would generate more revenue as well as fix the problem about "our demand isn't guaranteed."

One of their problems is a lack of creativity in their sales strategy.

Putting an HMO between the customer and the supplier, is part of this problem.

Regards,
Amy J
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News